These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

761 related items for PubMed ID: 23643157

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tissue gadolinium deposition in hepatorenally impaired rats exposed to Gd-EOB-DTPA: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T, Tamada T, Watanabe S, Nishimura H, Kanki A, Noda Y, Higaki A, Yamamoto A, Ito K.
    Radiol Med; 2015 Jun; 120(6):557-62. PubMed ID: 25572545
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
    Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA.
    Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
    [Abstract] [Full Text] [Related]

  • 5. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis.
    Birka M, Wentker KS, Lusmöller E, Arheilger B, Wehe CA, Sperling M, Stadler R, Karst U.
    Anal Chem; 2015 Mar 17; 87(6):3321-8. PubMed ID: 25708271
    [Abstract] [Full Text] [Related]

  • 6. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
    Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ.
    Invest Radiol; 2008 Jan 17; 43(1):65-75. PubMed ID: 18097279
    [Abstract] [Full Text] [Related]

  • 7. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
    Delfino R, Biasotto M, Candido R, Altissimo M, Stebel M, Salomè M, van Elteren JT, Vogel Mikuš K, Zennaro C, Šala M, Addobbati R, Tromba G, Pascolo L.
    Toxicol Lett; 2019 Feb 17; 301():157-167. PubMed ID: 30476537
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
    Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée JM, Corot C.
    Toxicol Sci; 2013 Jan 17; 131(1):259-70. PubMed ID: 22977165
    [Abstract] [Full Text] [Related]

  • 10. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H.
    Invest Radiol; 2017 Jun 17; 52(6):324-333. PubMed ID: 28323657
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
    Jia J, Puls D, Oswald S, Jedlitschky G, Kühn JP, Weitschies W, Hosten N, Siegmund W, Keiser M.
    Invest Radiol; 2014 Feb 17; 49(2):78-86. PubMed ID: 24056116
    [Abstract] [Full Text] [Related]

  • 14. Identification and quantification of potential metabolites of Gd-based contrast agents by electrochemistry/separations/mass spectrometry.
    Telgmann L, Faber H, Jahn S, Melles D, Simon H, Sperling M, Karst U.
    J Chromatogr A; 2012 Jun 01; 1240():147-55. PubMed ID: 22525874
    [Abstract] [Full Text] [Related]

  • 15. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL.
    J Am Acad Dermatol; 2010 Sep 01; 63(3):389-99. PubMed ID: 20619488
    [Abstract] [Full Text] [Related]

  • 16. Incorporation of excess gadolinium into human bone from medical contrast agents.
    Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE.
    Metallomics; 2009 Nov 01; 1(6):479-88. PubMed ID: 21305156
    [Abstract] [Full Text] [Related]

  • 17. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide.
    Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C.
    Br J Pharmacol; 2012 Feb 01; 165(4b):1151-62. PubMed ID: 21740412
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis: histology and gadolinium detection.
    Thakral C, Abraham JL.
    Radiol Clin North Am; 2009 Sep 01; 47(5):841-53, vi-vii. PubMed ID: 19744599
    [Abstract] [Full Text] [Related]

  • 19. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
    Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J.
    Exp Toxicol Pathol; 2009 Nov 01; 61(6):537-52. PubMed ID: 19131226
    [Abstract] [Full Text] [Related]

  • 20. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.
    Br J Dermatol; 2011 Oct 01; 165(4):828-36. PubMed ID: 21692765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.